Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Canadian guideline for Parkinson disease.

Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, Suchowersky O, Rajput A, Lafontaine AL, Mestre T, Appel-Cresswell S, Kalia SK, Schoffer K, Zurowski M, Postuma RB, Udow S, Fox S, Barbeau P, Hutton B.

CMAJ. 2019 Sep 9;191(36):E989-E1004. doi: 10.1503/cmaj.181504. No abstract available.

PMID:
31501181
2.

Transcranial magnetic stimulation improves cognition over time in Parkinson's disease.

Trung J, Hanganu A, Jobert S, Degroot C, Mejia-Constain B, Kibreab M, Bruneau MA, Lafontaine AL, Strafella A, Monchi O.

Parkinsonism Relat Disord. 2019 Jul 8. pii: S1353-8020(19)30296-2. doi: 10.1016/j.parkreldis.2019.07.006. [Epub ahead of print]

PMID:
31300260
3.

Why Is Aging a Risk Factor for Cognitive Impairment in Parkinson's Disease?-A Resting State fMRI Study.

Nagano-Saito A, Bellec P, Hanganu A, Jobert S, Mejia-Constain B, Degroot C, Lafontaine AL, Lissemore JI, Smart K, Benkelfat C, Monchi O.

Front Neurol. 2019 Mar 22;10:267. doi: 10.3389/fneur.2019.00267. eCollection 2019.

4.

Rheumatoid Meningitis Presenting With Acute Parkinsonism and Protracted Non-convulsive Seizures: An Unusual Case Presentation and Review of Treatment Strategies.

Pellerin D, Wodkowski M, Guiot MC, AlDhukair H, Blotsky A, Karamchandani J, Vinet E, Lafontaine AL, Lubarsky S.

Front Neurol. 2019 Feb 27;10:163. doi: 10.3389/fneur.2019.00163. eCollection 2019.

5.

Evaluating the content validity of generic preference-based measures for use in Parkinson's disease.

Kuspinar A, Mate K, Lafontaine AL, Mayo N.

Parkinsonism Relat Disord. 2019 May;62:112-116. doi: 10.1016/j.parkreldis.2019.01.014. Epub 2019 Jan 14.

PMID:
30685325
6.

Cerebral Metabolic Changes Related to Freezing of Gait in Parkinson Disease.

Mitchell T, Potvin-Desrochers A, Lafontaine AL, Monchi O, Thiel A, Paquette C.

J Nucl Med. 2019 May;60(5):671-676. doi: 10.2967/jnumed.118.218248. Epub 2018 Oct 12.

PMID:
30315142
7.

A 12-Week Cycling Training Regimen Improves Upper Limb Functions in People With Parkinson's Disease.

Nadeau A, Lungu O, Boré A, Plamondon R, Duchesne C, Robillard MÈ, Bobeuf F, Lafontaine AL, Gheysen F, Bherer L, Doyon J.

Front Hum Neurosci. 2018 Sep 11;12:351. doi: 10.3389/fnhum.2018.00351. eCollection 2018.

8.

Change in Cognition and Other Non-Motor Symptoms With Obstructive Sleep Apnea Treatment in Parkinson Disease.

Kaminska M, Mery VP, Lafontaine AL, Robinson A, Benedetti A, Gros P, Kimoff RJ.

J Clin Sleep Med. 2018 May 15;14(5):819-828. doi: 10.5664/jcsm.7114.

9.

White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease.

Hanganu A, Houde JC, Fonov VS, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V, Chouinard S, Collins LD, Descoteaux M, Monchi O.

Mov Disord. 2018 Jul;33(7):1139-1150. doi: 10.1002/mds.27364. Epub 2018 Apr 23.

PMID:
29683523
10.

Reduced cognitive function in patients with Parkinson disease and obstructive sleep apnea.

Mery VP, Gros P, Lafontaine AL, Robinson A, Benedetti A, Kimoff RJ, Kaminska M.

Neurology. 2017 Mar 21;88(12):1120-1128. doi: 10.1212/WNL.0000000000003738. Epub 2017 Feb 22.

PMID:
28228566
11.

A 12-Week Cycling Training Regimen Improves Gait and Executive Functions Concomitantly in People with Parkinson's Disease.

Nadeau A, Lungu O, Duchesne C, Robillard MÈ, Bore A, Bobeuf F, Plamondon R, Lafontaine AL, Gheysen F, Bherer L, Doyon J.

Front Hum Neurosci. 2017 Jan 12;10:690. doi: 10.3389/fnhum.2016.00690. eCollection 2016.

12.

Patterns of Longitudinal Neural Activity Linked to Different Cognitive Profiles in Parkinson's Disease.

Nagano-Saito A, Al-Azzawi MS, Hanganu A, Degroot C, Mejia-Constain B, Bedetti C, Lafontaine AL, Soland V, Chouinard S, Monchi O.

Front Aging Neurosci. 2016 Nov 23;8:275. eCollection 2016.

13.

Depressive symptoms in Parkinson's disease correlate with cortical atrophy over time.

Hanganu A, Bruneau MA, Degroot C, Bedetti C, Mejia-Constain B, Lafontaine AL, Chouinard S, Monchi O.

Brain Cogn. 2017 Feb;111:127-133. doi: 10.1016/j.bandc.2016.11.001. Epub 2016 Dec 4.

PMID:
27918935
14.

Influence of aerobic exercise training on the neural correlates of motor learning in Parkinson's disease individuals.

Duchesne C, Gheysen F, Bore A, Albouy G, Nadeau A, Robillard ME, Bobeuf F, Lafontaine AL, Lungu O, Bherer L, Doyon J.

Neuroimage Clin. 2016 Sep 14;12:559-569. eCollection 2016.

15.

Examining chronic care patient preferences for involvement in health-care decision making: the case of Parkinson's disease patients in a patient-centred clinic.

Zizzo N, Bell E, Lafontaine AL, Racine E.

Health Expect. 2017 Aug;20(4):655-664. doi: 10.1111/hex.12497. Epub 2016 Sep 14.

16.

Diagnosis of Obstructive Sleep Apnea in Parkinson's Disease Patients: Is Unattended Portable Monitoring a Suitable Tool?

Gros P, Mery VP, Lafontaine AL, Robinson A, Benedetti A, Kimoff RJ, Kaminska M.

Parkinsons Dis. 2015;2015:258418. doi: 10.1155/2015/258418. Epub 2015 Oct 13.

17.

The Interaction between Obstructive Sleep Apnea and Parkinson's Disease: Possible Mechanisms and Implications for Cognitive Function.

Kaminska M, Lafontaine AL, Kimoff RJ.

Parkinsons Dis. 2015;2015:849472. doi: 10.1155/2015/849472. Epub 2015 Oct 5. Review.

18.

Enhancing both motor and cognitive functioning in Parkinson's disease: Aerobic exercise as a rehabilitative intervention.

Duchesne C, Lungu O, Nadeau A, Robillard ME, Boré A, Bobeuf F, Lafontaine AL, Gheysen F, Bherer L, Doyon J.

Brain Cogn. 2015 Oct;99:68-77. doi: 10.1016/j.bandc.2015.07.005. Epub 2015 Aug 7.

PMID:
26263381
19.

Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime.

Gros P, Mery VP, Lafontaine AL, Robinson A, Benedetti A, Kimoff RJ, Kaminska M.

Sleep Breath. 2016 Mar;20(1):205-12. doi: 10.1007/s11325-015-1208-9. Epub 2015 Jun 13.

PMID:
26070532
20.

Influence of depressive symptoms on dopaminergic treatment of Parkinson's disease.

Hanganu A, Degroot C, Monchi O, Bedetti C, Mejia-Constain B, Lafontaine AL, Chouinard S, Bruneau MA.

Front Neurol. 2014 Sep 25;5:188. doi: 10.3389/fneur.2014.00188. eCollection 2014.

21.

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease.

Habak C, Noreau A, Nagano-Saito A, Mejía-Constaín B, Degroot C, Strafella AP, Chouinard S, Lafontaine AL, Rouleau GA, Monchi O.

Brain. 2014 Nov;137(Pt 11):3025-35. doi: 10.1093/brain/awu251. Epub 2014 Sep 10.

22.

Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally.

Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V, Chouinard S, Bruneau MA, Mellah S, Belleville S, Monchi O.

Brain. 2014 Apr;137(Pt 4):1120-9. doi: 10.1093/brain/awu036. Epub 2014 Mar 10.

PMID:
24613932
23.

Referrals, Wait Times and Diagnoses at an Urgent Neurology Clinic over 10 Years.

Wile DJ, Warner J, Murphy W, Lafontaine AL, Hanson A, Furtado S.

Can J Neurol Sci. 2014 Mar;41(2):260-4.

PMID:
24534040
24.

Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease.

Nagano-Saito A, Habak C, Mejía-Constaín B, Degroot C, Monetta L, Jubault T, Bedetti C, Lafontaine AL, Chouinard S, Soland V, Ptito A, Strafella AP, Monchi O.

Neurobiol Aging. 2014 Jan;35(1):223-31. doi: 10.1016/j.neurobiolaging.2013.06.025. Epub 2013 Aug 7.

PMID:
23932879
25.

Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration.

Hanganu A, Bedetti C, Jubault T, Gagnon JF, Mejia-Constain B, Degroot C, Lafontaine AL, Chouinard S, Monchi O.

Mov Disord. 2013 Sep;28(10):1360-9. doi: 10.1002/mds.25541. Epub 2013 Jun 25.

PMID:
23801590
26.

Canadian Guidelines on Parkinson's Disease.

Grimes D, Gordon J, Snelgrove B, Lim-Carter I, Fon E, Martin W, Wieler M, Suchowersky O, Rajput A, Lafontaine AL, Stoessl J, Moro E, Schoffer K, Miyasaki J, Hobson D, Mahmoudi M, Fox S, Postuma R, Kumar H, Jog M; Canadian Nourological Sciences Federation.

Can J Neurol Sci. 2012 Jul;39(4 Suppl 4):S1-30. No abstract available.

PMID:
23126020
27.

Whipple's disease presenting with segmental myoclonus and hypersomnia.

Xia C, Duquette A, Frucht S, Lafontaine AL.

Mov Disord. 2012 Sep 1;27(10):1216-7. doi: 10.1002/mds.24039. No abstract available.

PMID:
22976777
28.

Patterns of cortical thickness and surface area in early Parkinson's disease.

Jubault T, Gagnon JF, Karama S, Ptito A, Lafontaine AL, Evans AC, Monchi O.

Neuroimage. 2011 Mar 15;55(2):462-7. doi: 10.1016/j.neuroimage.2010.12.043. Epub 2010 Dec 22.

PMID:
21184830
29.

Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI.

Jubault T, Brambati SM, Degroot C, Kullmann B, Strafella AP, Lafontaine AL, Chouinard S, Monchi O.

PLoS One. 2009 Dec 10;4(12):e8247. doi: 10.1371/journal.pone.0008247.

30.

L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network.

Jubault T, Monetta L, Strafella AP, Lafontaine AL, Monchi O.

PLoS One. 2009 Jul 7;4(7):e6154. doi: 10.1371/journal.pone.0006154.

31.

Developments in neuroacanthocytosis: expanding the spectrum of choreatic syndromes.

Walker RH, Danek A, Dobson-Stone C, Guerrini R, Jung HH, Lafontaine AL, Rampoldi L, Tison F, Andermann E.

Mov Disord. 2006 Nov;21(11):1794-805. Review.

PMID:
16958034
32.

Myoclonus as an acute complication of low-dose hydromorphone in multiple system atrophy.

Hofmann A, Tangri N, Lafontaine AL, Postuma RB.

J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):994-5. No abstract available.

33.

Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.

Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, Ranawaya R, Camicioli R, Lang AE.

Neurology. 2006 Jun 27;66(12):1941-3.

PMID:
16801668
34.

A 52-year-old man with cognitive decline, seizure and stroke.

Simon JE, Parboosingh J, Clark A, George D, Lafontaine AL, Hill MD.

CMAJ. 2004 Apr 27;170(9):1393-4. No abstract available.

35.

Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.

Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O.

Mov Disord. 2002 Nov;17(6):1288-93.

PMID:
12465070
36.

PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.

DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH.

Am J Hum Genet. 2002 May;70(5):1089-95. Epub 2002 Mar 27.

37.

Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study.

Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, Stacy M, Myers RH.

Neurology. 2002 Jan 8;58(1):79-84. Erratum in: Neurology. 2002 Apr 9;58(7):1136.

PMID:
11781409
38.

Genome-wide scan for Parkinson's disease: the GenePD Study.

DeStefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, Feldman RG, Guttman M, Watts RL, Suchowersky O, Lafontaine AL, Labelle N, Lew MF, Waters CH, Growdon JH, Singer C, Currie LJ, Wooten GF, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Stacy M, Montgomery E, MacDonald ME, Gusella JF, Myers RH.

Neurology. 2001 Sep 25;57(6):1124-6.

PMID:
11571351
39.

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.

Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, Feigin A, Mazurkiewicz J, Ford B, Jennings D, Dilllon S, Comella C, Blasucci L, Janko K, Shulman L, Wiener W, Bateman-Rodriguez D, Carrion A, Suchowersky O, Lafontaine AL, Pantella C, Siemers E, Belden J, Davies R, Lannon M, Grimes D, Gray P, Martin W, Kennedy L, Adler C, Newman S, Hammerstad J, Stone C, Lewitt P, Bardram K, Mistura K, Miyasaki J, Johnston L, Cha JH, Tennis M, Panniset M, Hall J, Tetrud J, Friedlander J, Hauser R, Gauger L, Rodnitzky R, Deleo A, Dobson J, Seeberger L, Dingmann C, Tarsy D, Ryan P, Elmer L, Ruzicka D, Stacy M, Brewer M, Locke B, Baker D, Casaceli C, Day D, Florack M, Hodgeman K, Laroia N, Nobel R, Orme C, Rexo L, Rothenburgh K, Sulimowicz K, Watts A, Wratni E, Tariot P, Cox C, Leventhal C, Alderfer V, Craun AM, Frey J, McCree L, McDermott J, Cooper J, Holdich T, Read B; Parkinson Study Group.

Neurology. 2001 Feb 27;56(4):455-62.

PMID:
11222787
40.

Bilateral focal polymicrogyria in Ehlers-Danlos syndrome.

Echaniz-Laguna A, de Saint-Martin A, Lafontaine AL, Tasch E, Thomas P, Hirsh E, Marescaux C, Andermann F.

Arch Neurol. 2000 Jan;57(1):123-7.

PMID:
10634459

Supplemental Content

Loading ...
Support Center